Vutrisiran clinical trials
Also written ALN-TTRSC02 and AMVUTTRA.
How each study uses vutrisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vutrisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Jun 2022 · AMVUTTRA · NDA 215515 (FDA, Drugs@FDA)
- European Union
- 15 Sept 2022 · Amvuttra · EMEA/H/C/005852 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses vutrisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyEnrolling by invitationPhase 3Alnylam PharmaceuticalsNCT06679946Written as Vutrisiran
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyActive, not recruitingPhase 3Alnylam PharmaceuticalsNCT04153149Written as Vutrisiran
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)CompletedPhase 3Alnylam PharmaceuticalsNCT03759379Written as Vutrisiran
- A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy SubjectsCompletedPhase 1Alnylam PharmaceuticalsNCT02797847Written as ALN-TTRSC02
Given beside what is tested · 1 — vutrisiran is usual care or a partner of the new treatment
Codes
What other systems call vutrisiran · ClinicalTrials.gg INT002160
- MeSH (NLM) C000731927vutrisiranOne source NLM
- UNII (FDA) GB4I2JI8UIVUTRISIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2604578One source FDA
- Wikidata Q112620160vutrisiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152919VutrisiranOne source FDA
- DrugBank DB16699One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731927 | vutrisiran | One source NLM |
| UNII (FDA) | GB4I2JI8UI | VUTRISIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2604578 | — | One source FDA |
| Wikidata | Q112620160 | vutrisiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152919 | Vutrisiran | One source FDA |
| DrugBank | DB16699 | — | One source Wikidata |
Also registered as vutrisiran sodium (UNII 28O0WP6Z1P · RxNorm 2605574).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.